Medexus Pharmaceuticals announced that the US Food and Drug Administration (FDA) recently approved Medexus's supplemental Biologics License Application (sBLA) for IXINITY® [coagulation factor IX (recombinant] for the on-demand, prophylactic, and perioperative treatment of pediatric patients under 12 years of age with hemophilia B. IXINITY®, an intravenous recombinant factor IX therapeutic, is now approved for use in all patients with hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood. The sBLA and expanded indication for IXINITY® are based on results from a Phase 3/4 study that evaluated the pharmacokinetics (PK), safety, and efficacy of IXINITY® as a prophylactic treatment in previously treated pediatric patients under 12 years of age with severe or moderately severe hemophilia B. The study demonstrated that prophylaxis with IXINITY® was associated with low annualized bleeding rates, effective control of bleeding episodes, consistent PK, and a consistent safety profile.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.82 CAD | -3.70% | +10.30% | -26.32% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.32% | 32.39M | |
+34.00% | 704B | |
+29.29% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+13.79% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- MDP Stock
- News Medexus Pharmaceuticals Inc.
- Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R)